Singapore, Aug. 7 -- Energenesis Biomedical has entered into a joint development agreement with Taiwan Tanabe Seiyaku, the wholly owned subsidiary of Tanabe Pharma Corporation, for ENERGI-F703DFU, Energenesis' investigational topical drug for diabetic foot ulcers (DFU).

Under the agreement, Energenesis and Taiwan Tanabe will collaborate on process technology transfer and CMC activities intended to support a potential NDA for ENERGI-F703DFU in Taiwan.

The parties also plan to advance discussions regarding future manufacturing and commercialisation licenses in Taiwan and selected ASEAN markets, subject to separate definitive agreements and applicable regulatory approvals.

The collaboration brings together Energenesis' proprietary ENERGI ...